Submission Details
| 510(k) Number | K241770 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | June 20, 2024 |
| Decision Date | March 05, 2025 |
| Days to Decision | 258 days |
| Submission Type | Traditional |
| Review Panel | Radiology (RA) |
| Summary | Summary PDF |
K241770 is an FDA 510(k) clearance for the Prostate MR AI (VA10A), a Radiological Computer Assisted Detection/diagnosis Software For Lesions Suspicious For Cancer (Class II — Special Controls, product code QDQ), submitted by Siemens Healthcare GmbH (Erlanger, DE). The FDA issued a Cleared decision on March 5, 2025, 258 days after receiving the submission on June 20, 2024. This device falls under the Radiology review panel. Regulated under 21 CFR 892.2090.
| 510(k) Number | K241770 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | June 20, 2024 |
| Decision Date | March 05, 2025 |
| Days to Decision | 258 days |
| Submission Type | Traditional |
| Review Panel | Radiology (RA) |
| Summary | Summary PDF |
| Product Code | QDQ — Radiological Computer Assisted Detection/diagnosis Software For Lesions Suspicious For Cancer |
| Device Class | Class II — Special Controls |
| CFR Regulation | 21 CFR 892.2090 |
| Definition | A Radiological Computer Assisted Detection And Diagnostic Software For Suspected Lesions Is An Image Processing Device Intended To Aid In The Detection, Localization, And Characterization Of Lesions Suspicious For Cancer On Acquired Medical Images (e.g., Mammography , Mr, Ct, Ultrasound, Radiography). The Device Detects, Identifies And Characterizes Lesions Suspicious For Cancer Based On Features Or Information Extracted From The Images, And May Provide Information About The Presence, Location, And Characteristics Of The Lesion To The User. Primary Diagnostic And Patient Management Decisions Are Made By The Clinical User. |